Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
September 08 2021 - 8:13AM
Business Wire
National Resilience, Inc. (Resilience), a company seeking to
build the world’s most advanced biopharmaceutical manufacturing
ecosystem, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology
company pioneering messenger RNA (mRNA) medicines, today announced
an agreement to manufacture drug substance for the Moderna COVID-19
vaccine.
Under the terms of the multi-year agreement, Resilience will
produce mRNA for the Moderna COVID-19 vaccine at its facility in
Mississauga, Ontario in Canada, for distribution worldwide.
“Moderna’s COVID-19 vaccine has saved countless lives, and we’re
excited to manufacture mRNA for this important vaccine,” said Rahul
Singhvi, Sc.D, Chief Executive Officer of Resilience. “This
collaboration has the potential to ensure more people are protected
around the world from the deadly COVID-19 virus.”
Separately, Moderna recently announced a collaboration to bring
mRNA manufacturing to Canada through a Memorandum of Understanding
(MoU) with the government of Canada to build a state-of-the-art
messenger RNA (mRNA) vaccine manufacturing facility in the country
including access to Moderna’s mRNA development engine. The goals of
this MoU are to build the foundation to support Canada with direct
access to rapid pandemic response capabilities and to provide
access to Moderna’s vaccines in development for respiratory
viruses.
About Resilience
Resilience is a manufacturing and technology company dedicated
to broadening access to complex medicines and protecting
biopharmaceutical supply chains against disruption. Founded in
2020, the company is building a sustainable network of high-tech,
end-to-end manufacturing solutions with the aim to ensure the
medicines of today and tomorrow can be made quickly, safely, and at
scale. Resilience seeks to offer the highest quality and regulatory
capabilities, and flexible and adaptive facilities to serve
partners of all sizes. By continuously advancing the science of
biopharmaceutical manufacturing and development, Resilience aims to
free partners to focus on the discoveries that improve patients’
lives.
For more information, visit www.Resilience.com.
About Moderna
In 10 years since its inception, Moderna has transformed from a
science research-stage company advancing programs in the field of
messenger RNA (mRNA), to an enterprise with a diverse clinical
portfolio of vaccines and therapeutics across six modalities, a
broad intellectual property portfolio in areas including mRNA and
lipid nanoparticle formulation, and an integrated manufacturing
plant that allows for both clinical and commercial production at
scale and at unprecedented speed.
Moderna maintains alliances with a broad range of domestic and
overseas government and commercial collaborators, which has allowed
for the pursuit of both groundbreaking science and rapid scaling of
manufacturing. Most recently, Moderna’s capabilities have come
together to allow the authorized use of one of the earliest and
most-effective vaccines against the COVID-19 pandemic.
Moderna’s mRNA platform builds on continuous advances in basic
and applied mRNA science, delivery technology and manufacturing,
and has allowed the development of therapeutics and vaccines for
infectious diseases, immuno-oncology, rare diseases, cardiovascular
diseases and auto-immune diseases. Moderna has been named a top
biopharmaceutical employer by Science for the past six years. To
learn more, visit www.modernatx.com.
Moderna Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including regarding: Moderna’s development of a
vaccine against COVID-19; plans for the manufacturing of mRNA by
National Resilience for the Moderna COVID-19 Vaccine; and the
Company’s collaboration with the Canadian government to develop
mRNA manufacturing facilities in Canada to provide pandemic
response capabilities. The forward-looking statements in this press
release are neither promises nor guarantees, and you should not
place undue reliance on these forward-looking statements because
they involve known and unknown risks, uncertainties, and other
factors, many of which are beyond Moderna’s control and which could
cause actual results to differ materially from those expressed or
implied by these forward-looking statements. These risks,
uncertainties, and other factors include those other risks and
uncertainties described under the heading “Risk Factors” in
Moderna’s most recent Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission (SEC) and in subsequent
filings made by Moderna with the SEC, which are available on the
SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising
any forward-looking statements contained in this press release in
the event of new information, future developments or otherwise.
These forward-looking statements are based on Moderna’s current
expectations and speak only as of the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210908005677/en/
Resilience: Ryan Flinn Head of Communications
Ryan.flinn@Resilience.com 510-207-7616 Moderna:
Media: Colleen Hussey Director, Corporate Communications
617-335-1374 Colleen.Hussey@modernatx.com Investors: Lavina
Talukdar Senior Vice President & Head of Investor Relations
617-209-5834 Lavina.Talukdar@modernatx.com
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Apr 2024 to May 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From May 2023 to May 2024